CDK7 and small cell lung carcinoma: The more specific CDK7 inhibitor YKL-5–124 was found to predominately disrupt cell cycle progression while simultaneously triggering immune response signaling in SCLC, which provides a rationale for new combination regimens consisting of CDK7 inhibitors and immunotherapy (15).